The Challenge of Finding the Unknown

Inobrodib is being developed as a first-in-class oral cancer drug that the company says will be able to treat not only multiple myeloma, but other specific cancers as well.

In this episode, Hanns-Christian Mahler from ten23 Health chats about the advances in fill/finish.

Researchers say they have discovered the first drug mechanism that binds to the pyrin domain to block NLRP3 and prevent a series of reactions resulting in inflammation.

In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.

Six winners and two honorable mentions were revealed at ISPE’s Europe Annual Conference in London.

According to the White House, the order builds on actions taken in the president’s first term to reduce price disparities domestically.